BIOMAT Database Logo BIOMAT Database Logo

Moxifloxacin-rifampicin combination for the treatment of non-staphylococcal Gram-positive orthopedic implant-related infections. 2019

F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
Unité des maladies infectieuses, hôpital Broussais, 1, rue de la Marne, 35400 Saint-Malo, France; Centre de référence pour les infections ostéoarticulaires complexes du Grand Ouest (CRIOGO), centre hospitalier universitaire de Rennes, 2, rue Henri-le-Guilloux, 35033 Rennes, France. Electronic address: f.fily@ch-stmalo.fr.

OBJECTIVE We aimed to describe the effectiveness and safety of the moxifloxacin-rifampicin combination in non-staphylococcal Gram-positive orthopedic implant-related infections. METHODS Patients treated with the moxifloxacin-rifampicin combination for an implant-related infection from November 2014 to November 2016 were retrospectively identified from the database of the referral centers for bone and joint infections in Western France. RESULTS Twenty-three cases of infection due to Streptococcus spp. (n=12), Cutibacteriumacnes (n=6), and Enterococcus faecalis (n=5) were included. Ten patients with hip prosthesis were included. Infection was polymicrobial in 11 cases. According to the MIC, moxifloxacin was 1.5 to 11.7 times as active as levofloxacin against non-staphylococcal Gram-positive bacteria. We reported an 81.8% success rate, and no severe adverse effect. CONCLUSIONS The moxifloxacin-rifampicin combination is a valuable alternative for the treatment of non-staphylococcal Gram-positive implant-related infections because of the good activity of moxifloxacin against these bacteria and the potential activity on the biofilm.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011423 Propionibacteriaceae A family of gram-positive bacteria found in dairy products or in the intestinal tracts of animals.
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006622 Hip Prosthesis Replacement for a hip joint. Femoral Head Prosthesis,Femoral Head Prostheses,Hip Prostheses,Prostheses, Femoral Head,Prostheses, Hip,Prosthesis, Femoral Head,Prosthesis, Hip
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077266 Moxifloxacin A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent. 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,Actira,Avalox,Avelox,BAY 12-8039,BAY 128039,BAY-12-8039,BAY-128039,Izilox,Moxifloxacin Hydrochloride,Octegra,Proflox,BAY 12 8039,BAY128039
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections.
December 2010, Antimicrobial agents and chemotherapy,
F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
[Netilmicin and netilmicin-rifampicin combination in targeted treatment of staphylococcal infections].
September 1986, La Clinica terapeutica,
F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
[Efficacy and tolerability of linezolid therapy in the treatment of orthopedic implant infections caused by gram-positive multiresistant cocci].
March 2010, Revista clinica espanola,
F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
[Treatment of severe staphylococcal infections. Failure of rifampicin in combination therapy. 4 cases].
May 1985, Presse medicale (Paris, France : 1983),
F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
Effectiveness of oral antibiotics for definitive therapy of non-Staphylococcal Gram-positive bacterial bloodstream infections.
January 2019, Therapeutic advances in infectious disease,
F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
Automated ribotyping to distinguish the different non Sau/ non Sep staphylococcal emerging pathogens in orthopedic implant infections.
April 2006, The International journal of artificial organs,
F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations.
June 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
[Rifampicin in staphylococcal infections].
January 1982, Giornale italiano di chemioterapia,
F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
Chronic Suppressive Antibiotic Treatment for Staphylococcal Bone and Joint Implant-Related Infections.
May 2023, Antibiotics (Basel, Switzerland),
F Fily, and A Jolivet-Gougeon, and E Polard, and T Gicquel, and M Dupont, and M C Verdier, and C Arvieux
[Treatment of orthopedic implant-associated infections].
October 2019, Lakartidningen,
Copied contents to your clipboard!